Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.66 | N/A | -9.45% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.66 | N/A | -9.45% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding the company's near-term performance. They highlighted the importance of maintaining strategic initiatives amidst market pressures.
Management acknowledged the ongoing challenges in the current market environment.
They emphasized a focus on long-term strategies despite short-term setbacks.
The earnings report indicates that Scholar Rock is facing challenges, as evidenced by the missed EPS target. The stock's reaction, dropping 5.29%, reflects investor concerns about the company's current performance and lack of guidance. Without revenue figures or a clear outlook, uncertainty remains high for future quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ICL GROUP LTD
Nov 11, 2024